Congress highlights
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼

LOOK FOR
REPATHA® AND AMGEN
AT MAJOR CARDIOLOGY
CONGRESSES

Repatha® at ESC Congress 2020

ESC Congress 2020 – The Digital Experience pushed new boundaries by bringing together an even larger cardiology community for an exclusively online programme of groundbreaking science.
Important new data were discussed during the Congress, including the suboptimal control of LDL-C in cardiovascular patients across Europe, the value of lipid-lowering therapy combinations such as PCSK9 inhibitors added to optimised statins to improve LDL-C goal attainment, and real-world experience with Repatha® (evolocumab) in routine clinical practice.1,2

Key studies presented at ESC 2020:

DA VINCI Study1

  • An EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care.
  • The study highlights the gap between ESC/EAS Guideline-recommended LDL-C goals3 and clinical practice across a broad range of patients.1

HEYMANS Study2

  • A multicentre, observational cohort study conducted in 10 European countries involving patients with hyperlipidaemia initiating Repatha®.
  • Repatha® use in routine clinical practice is aligned with 2016 clinical guidelines4 and has very high rates of patient compliance and persistence†5 which should offer significant benefits in these very-high-risk patients with ASCVD.

*All patients received high-intensity statins unless contraindicated and were treated in accordance with current ACS guidelines.
Patient compliance and persistence was the secondary endpoint of this study.
25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
§In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; ASCVD = Atherosclerotic Cardiovascular disease; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EU = European Union; LDL-C = Low-density lipoprotein cholesterol; PCSK9 = Proprotein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.
  1. Ray KK, et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol 2020; zwaa047.
  2. Ray KK, et al. Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study. Eur Heart J 2020;41(Suppl.2): ehaa946.3013.
  3. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88.
  4. Catapano AL, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 Oct 14;37(39):2999-3058.
  5. Ray KK, et al. P1699. Presented at European Society of Cardiology (ESC) Congress, Munich, Germany; August 25–29, 2018. doi. 10.1093/eurheartj/ehy565.P1699.
  6. Gencer B, et al. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. JAMA Cardiol. 2020;5(8):952-957. Main paper & Supplementary appendix.